Study of Cognitive-Linguistic Profiles: The Role of Executive Control in Aphasia

NCT07766356 | Not Yet Recruiting DMC

• 2 other identifiers: RC31/25/0614ID-RCB
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

In France, stroke affects 150,000 people annually and is the leading cause of acquired disability in adults; 10-12% of patients exhibit mild post-stroke aphasia, a condition defined by language difficulties. Few studies describe mild post-stroke aphasia, and none characterize the impairment of linguistic executive control in this population; consequently, its prevalence remains unknown. To date, the role of linguistic executive control in mild aphasia remains an open question. The aim of this project is to investigate linguistic executive control impairment in stroke survivors with mild aphasia, provide an initial estimate of its prevalence, and demonstrate its interactions with other linguistic and communicative aspects, as well as with executive and attentional functions.

Conditions

Stroke

Keywords

stroke; aphasia; AVC

Outcome Measures

Primary Outcomes (1)

• measure the proportion of patients with mild post-stroke aphasia exhibiting deficits in linguistic executive control within three months of a first stroke

  CATEX score result (deficit score if below the mean value minus 1.65 times the standard deviation)

  7 days after the inclusion

Secondary Outcomes (6)

• Study of the correlation between executive control of language (CATEX score) and the score of the test evaluating access to the lexical stock

  7 days after the inclusion

• Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating access to the semantic system

  7 days after the inclusion

• Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating non-verbal executive control

  7 days after the inclusion

• Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating gnosies

  7 days after the inclusion

• Identification of patients' cognitive-linguistic impairment profiles based on cognitive test scores

  7 days after the inclusion

Study Arms (1)

Patients whose neuropsychological and speech-language pathology tests will be randomized

EXPERIMENTAL

Diagnostic Test: Neuropsychological tests; Diagnostic Test: Speech-language assessments

Interventions

Neuropsychological tests DIAGNOSTIC_TEST

Patients undergo neuropsychological tests, the order of which will be randomized.

Patients whose neuropsychological and speech-language pathology tests will be randomized

Speech-language assessments DIAGNOSTIC_TEST

Patients will undergo speech-language assessments, with the order of the tests randomized.

Patients whose neuropsychological and speech-language pathology tests will be randomized

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient who has experienced a first ischemic stroke resulting in clinical symptoms within the last 3 months and is receiving care in the Physical Medicine and Rehabilitation department.
• Score ≤ 31 on the conversational speech observation scale of the MEC test (Montreal Protocol for the Evaluation of Communication).
• Patients with a BDAE score ≥ 3 (Boston Diagnostic Aphasia Examination - French version, Mazaux J.-M. \[1990\]); this score is the gold standard in aphasiology.
• Native French-speaking patient capable of understanding oral or written instructions.

You may not qualify if:

• Patients exhibiting behavior or a clinical condition incompatible with test administration, as assessed by the clinician.
• Known major visual, auditory, or motor impairments incompatible with test performance.
• Known neurodegenerative and/or neurodevelopmental disorders.
• Known social cognition disorders (e.g., ASD).

Sponsors & Collaborators

• University Hospital, Toulouse: lead

Study Sites (1)

Service de Médecine Physique et de Réadaptation Hôpital Raymonde Fournet Purpan

Toulouse, 31300, France

Location

MeSH Terms

Conditions

Stroke; Aphasia

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Speech Disorders; Language Disorders; Communication Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Elodie GUILLOUET

CONTACT

0561779072; guillouet.E@chu-toulouse.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 20, 2026
• First Posted: August 14, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): September 8, 2028
• Last Updated: August 14, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)